A revolution: biotech patents in India
It has taken a long time for India to develop a productive environment for biotechnology. But recent developments look to have put it on the right track. Archana Shanker explains.
Recognising equivalence, reciprocity and respect
Homologation (recognition of equivalence) is a useful tool for simplifying administrative processes that are repeated in different countries. Nevertheless, it is not an end in itself.
Banning the patenting of biological materials in Australia: fact v fiction
An Australian legislative bill could have grave consequences for the country’s life sciences industry and, potentially, for patients as well. Tania Obranovich explains.
Windows of opportunity and closing doors at the EPO
There is a general acceptance that European patent law is complicated, particularly in the area of pharmaceutical inventions. Claire Baldock looks at how the EPO approaches these inventions.
Patenting life
A case before the Court of Justice for the European Union threatens to radically redraw the patent landscape for embryonic stem cells. Ashley Roughton explains.
Myriad issues for gene patents
A recent US district court ruling could significantly affect companies that patent genes and threaten the health of an entire industry. LSIPR investigates.
What next for stem cell research?
The European Court of Justice is faced with a crucial decision on stem cell research. Justin Turner QC explains.
New rules for French patents
Following the implementation of EU Directive 2004/48/EC on the enforcement of IP rights under French patent law in 2007 and the publication of the corresponding implementing rules in 2008, the criteria adopted by the French courts to grant preliminary injunctions have also changed.
The risk of narrow protection
A growing number of biotechnology inventions relate to peptides, oligonucleotides and other small molecules that could be used in therapeutic applications. Caroline Pallard explains the challenges of patenting such inventions.
Stricter examination requirements in Canada
Two pharmaceutical cases highlight recent developments in Canadian patent law relating to duty of candour during patent prosecution and patent claim construction, says Katie Wang.
